Last reviewed · How we verify
bimatoprost ophthalmic solution 0.015%
At a glance
| Generic name | bimatoprost ophthalmic solution 0.015% |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence (PHASE2)
- Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bimatoprost ophthalmic solution 0.015% CI brief — competitive landscape report
- bimatoprost ophthalmic solution 0.015% updates RSS · CI watch RSS
- Allergan portfolio CI